Switch to:
Also traded in: Austria, France, Germany, Italy, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.66
SNY's Cash-to-Debt is ranked lower than
69% of the 886 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.53 vs. SNY: 0.66 )
Ranked among companies with meaningful Cash-to-Debt only.
SNY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.14  Med: 0.56 Max: 10.62
Current: 0.66
0.14
10.62
Equity-to-Asset 0.58
SNY's Equity-to-Asset is ranked lower than
58% of the 801 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. SNY: 0.58 )
Ranked among companies with meaningful Equity-to-Asset only.
SNY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.48  Med: 0.58 Max: 0.65
Current: 0.58
0.48
0.65
Debt-to-Equity 0.27
SNY's Debt-to-Equity is ranked higher than
55% of the 540 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. SNY: 0.27 )
Ranked among companies with meaningful Debt-to-Equity only.
SNY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.06  Med: 0.18 Max: 0.39
Current: 0.27
0.06
0.39
Debt-to-EBITDA 1.68
SNY's Debt-to-EBITDA is ranked higher than
52% of the 522 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.83 vs. SNY: 1.68 )
Ranked among companies with meaningful Debt-to-EBITDA only.
SNY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.57  Med: 1.38 Max: 2.04
Current: 1.68
0.57
2.04
Interest Coverage 78.27
SNY's Interest Coverage is ranked lower than
67% of the 683 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 132.39 vs. SNY: 78.27 )
Ranked among companies with meaningful Interest Coverage only.
SNY' s Interest Coverage Range Over the Past 10 Years
Min: 9.31  Med: 18.68 Max: 78.27
Current: 78.27
9.31
78.27
Piotroski F-Score: 7
Altman Z-Score: 1.86
Beneish M-Score: -2.37
WACC vs ROIC
5.25%
7.47%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 19.89
SNY's Operating Margin % is ranked higher than
72% of the 819 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.96 vs. SNY: 19.89 )
Ranked among companies with meaningful Operating Margin % only.
SNY' s Operating Margin % Range Over the Past 10 Years
Min: 18.11  Med: 20.66 Max: 24.54
Current: 19.89
18.11
24.54
Net Margin % 23.30
SNY's Net Margin % is ranked higher than
90% of the 819 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.73 vs. SNY: 23.30 )
Ranked among companies with meaningful Net Margin % only.
SNY' s Net Margin % Range Over the Past 10 Years
Min: 11.88  Med: 13.66 Max: 23.3
Current: 23.3
11.88
23.3
ROE % 14.60
SNY's ROE % is ranked higher than
75% of the 857 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.75 vs. SNY: 14.60 )
Ranked among companies with meaningful ROE % only.
SNY' s ROE % Range Over the Past 10 Years
Min: 6.5  Med: 8.61 Max: 14.6
Current: 14.6
6.5
14.6
ROA % 8.26
SNY's ROA % is ranked higher than
73% of the 888 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.29 vs. SNY: 8.26 )
Ranked among companies with meaningful ROA % only.
SNY' s ROA % Range Over the Past 10 Years
Min: 3.78  Med: 5.11 Max: 8.26
Current: 8.26
3.78
8.26
ROC (Joel Greenblatt) % 52.69
SNY's ROC (Joel Greenblatt) % is ranked higher than
87% of the 869 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.64 vs. SNY: 52.69 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SNY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 33.19  Med: 45.49 Max: 56.76
Current: 52.69
33.19
56.76
3-Year Revenue Growth Rate 5.90
SNY's 3-Year Revenue Growth Rate is ranked higher than
52% of the 681 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. SNY: 5.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
SNY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -3.5  Med: 6.1 Max: 27.4
Current: 5.9
-3.5
27.4
3-Year EBITDA Growth Rate 1.20
SNY's 3-Year EBITDA Growth Rate is ranked lower than
64% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.90 vs. SNY: 1.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
SNY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -6.6  Med: 2.05 Max: 35.5
Current: 1.2
-6.6
35.5
3-Year EPS without NRI Growth Rate -3.20
SNY's 3-Year EPS without NRI Growth Rate is ranked lower than
67% of the 657 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.20 vs. SNY: -3.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
SNY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -12.8  Med: 1.25 Max: 41.7
Current: -3.2
-12.8
41.7
GuruFocus has detected 2 Warning Signs with Sanofi SA SNY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SNY's 30-Y Financials

Financials (Next Earnings Date: 2018-04-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2017

SNY Guru Trades in Q1 2017

John Rogers 17,794 sh (New)
Manning & Napier Advisors, Inc 244,282 sh (+8.00%)
Charles Brandes 3,490,226 sh (+3.03%)
NWQ Managers 497,766 sh (+2.91%)
Ken Fisher 12,615,505 sh (+0.99%)
Barrow, Hanley, Mewhinney & Strauss 29,418,481 sh (+0.14%)
John Buckingham 93,401 sh (+0.03%)
Warren Buffett 3,905,875 sh (unchged)
Murray Stahl 26,697 sh (unchged)
Francis Chou 410,000 sh (unchged)
Bill Nygren Sold Out
David Dreman Sold Out
PRIMECAP Management 2,024,807 sh (-0.61%)
Dodge & Cox 67,977,413 sh (-0.78%)
Joel Greenblatt 32,588 sh (-1.34%)
HOTCHKIS & WILEY 10,364,345 sh (-8.59%)
Sarah Ketterer 305,620 sh (-13.38%)
John Paulson 150,000 sh (-40.71%)
» More
Q2 2017

SNY Guru Trades in Q2 2017

David Dreman 132 sh (New)
Ken Fisher 13,638,458 sh (+8.11%)
John Buckingham 95,974 sh (+2.75%)
Manning & Napier Advisors, Inc 244,412 sh (+0.05%)
Warren Buffett 3,905,875 sh (unchged)
Joel Greenblatt 32,588 sh (unchged)
Francis Chou 410,000 sh (unchged)
John Rogers 17,790 sh (-0.02%)
Charles Brandes 3,455,511 sh (-0.99%)
PRIMECAP Management 1,982,707 sh (-2.08%)
Murray Stahl 25,697 sh (-3.75%)
Dodge & Cox 62,683,955 sh (-7.79%)
Barrow, Hanley, Mewhinney & Strauss 25,306,756 sh (-13.98%)
NWQ Managers 394,104 sh (-20.83%)
HOTCHKIS & WILEY 5,825,348 sh (-43.79%)
John Paulson 52,000 sh (-65.33%)
Sarah Ketterer 97,036 sh (-68.25%)
» More
Q3 2017

SNY Guru Trades in Q3 2017

Ken Fisher 14,082,257 sh (+3.25%)
John Buckingham 96,816 sh (+0.88%)
HOTCHKIS & WILEY 5,863,945 sh (+0.66%)
John Rogers 17,790 sh (unchged)
David Dreman 132 sh (unchged)
Murray Stahl 25,697 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
Francis Chou 410,000 sh (unchged)
Joel Greenblatt Sold Out
John Paulson Sold Out
Manning & Napier Advisors, Inc 243,175 sh (-0.51%)
Dodge & Cox 62,183,081 sh (-0.80%)
PRIMECAP Management 1,966,014 sh (-0.84%)
NWQ Managers 379,673 sh (-3.66%)
Barrow, Hanley, Mewhinney & Strauss 23,966,549 sh (-5.30%)
Charles Brandes 2,200,808 sh (-36.31%)
Sarah Ketterer 575 sh (-99.41%)
» More
Q4 2017

SNY Guru Trades in Q4 2017

John Buckingham 100,185 sh (+3.48%)
Ken Fisher 14,500,758 sh (+2.97%)
Charles Brandes 2,227,704 sh (+1.22%)
David Dreman 132 sh (unchged)
John Rogers 17,790 sh (unchged)
Murray Stahl 25,697 sh (unchged)
Francis Chou 410,000 sh (unchged)
Dodge & Cox 62,080,354 sh (-0.17%)
PRIMECAP Management 1,956,000 sh (-0.51%)
Warren Buffett 3,878,524 sh (-0.70%)
HOTCHKIS & WILEY 5,799,045 sh (-1.11%)
NWQ Managers 369,252 sh (-2.74%)
Barrow, Hanley, Mewhinney & Strauss 22,378,817 sh (-6.62%)
Sarah Ketterer 361 sh (-37.22%)
» More
» Details

Insider Trades

Latest Guru Trades with SNY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Dodge & Cox 2017-12-31 Reduce -0.17%$42.86 - $50.61 $ 39.96-13%62,080,354
Barrow, Hanley, Mewhinney & Strauss 2017-12-31 Reduce -6.62%0.12%$42.86 - $50.61 $ 39.96-13%22,378,817
Ken Fisher 2017-12-31 Add 2.97%0.02%$42.86 - $50.61 $ 39.96-13%14,500,758
HOTCHKIS & WILEY 2017-12-31 Reduce -1.11%0.01%$42.86 - $50.61 $ 39.96-13%5,799,045
Warren Buffett 2017-12-31 Reduce -0.70%$42.86 - $50.61 $ 39.96-13%3,878,524
Charles Brandes 2017-12-31 Add 1.22%0.02%$42.86 - $50.61 $ 39.96-13%2,227,704
NWQ Managers 2017-12-31 Reduce -2.74%0.01%$42.86 - $50.61 $ 39.96-13%369,252
Dodge & Cox 2017-09-30 Reduce -0.80%0.02%$46.81 - $50.34 $ 39.96-17%62,183,081
Barrow, Hanley, Mewhinney & Strauss 2017-09-30 Reduce -5.30%0.1%$46.81 - $50.34 $ 39.96-17%23,966,549
Ken Fisher 2017-09-30 Add 3.25%0.03%$46.81 - $50.34 $ 39.96-17%14,082,257
HOTCHKIS & WILEY 2017-09-30 Add 0.66%0.01%$46.81 - $50.34 $ 39.96-17%5,863,945
Charles Brandes 2017-09-30 Reduce -36.31%0.95%$46.81 - $50.34 $ 39.96-17%2,200,808
NWQ Managers 2017-09-30 Reduce -3.66%0.01%$46.81 - $50.34 $ 39.96-17%379,673
John Paulson 2017-09-30 Sold Out 0.03%$46.81 - $50.34 $ 39.96-17%0
Joel Greenblatt 2017-09-30 Sold Out 0.02%$46.81 - $50.34 $ 39.96-17%0
Dodge & Cox 2017-06-30 Reduce -7.79%0.2%$44.09 - $50.21 $ 39.96-16%62,683,955
Barrow, Hanley, Mewhinney & Strauss 2017-06-30 Reduce -13.98%0.28%$44.09 - $50.21 $ 39.96-16%25,306,756
Ken Fisher 2017-06-30 Add 8.11%0.08%$44.09 - $50.21 $ 39.96-16%13,638,458
HOTCHKIS & WILEY 2017-06-30 Reduce -43.79%0.81%$44.09 - $50.21 $ 39.96-16%5,825,348
Charles Brandes 2017-06-30 Reduce -0.99%0.02%$44.09 - $50.21 $ 39.96-16%3,455,511
NWQ Managers 2017-06-30 Reduce -20.83%0.06%$44.09 - $50.21 $ 39.96-16%394,104
John Paulson 2017-06-30 Reduce -65.33%0.06%$44.09 - $50.21 $ 39.96-16%52,000
John Rogers 2017-06-30 Reduce -0.02%$44.09 - $50.21 $ 39.96-16%17,790
David Dreman 2017-06-30 New Buy$44.09 - $50.21 $ 39.96-16%132
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:NYSE:BMY, XTER:BAYN, LSE:GSK, LSE:AZN, NYSE:LLY, NYSE:MRK, NYSE:ABBV, TSE:4503, TSE:4519, TSE:4578, TSE:4568, HKSE:01093, TSE:4528, XSWX:NOVN, TSE:4151, SHSE:600436, MIL:REC, SHSE:600867, BOM:500087, BOM:500302 » details
Traded in other countries:SANO.Austria, SAN.France, SNW.Germany, SANF.Italy, SNYN.Mexico, SAN.Switzerland, 0O59.UK, SNYNF.USA,
Headquarter Location:France
Sanofi SA is healthcare company which is engaged in the research, development, manufacture and marketing of therapeutic solutions. It business activities include operations of specialty care, Established Prescription Products and vaccines operations.

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. The company offers a diverse array of drugs with its highest revenue generator, Lantus, representing just over 10% of total sales. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent most of the remainder of sales.

Guru Investment Theses on Sanofi SA

First Eagle Investments Comments on Sanofi - Oct 24, 2016

Sanofi (NYSE:SNY) is a French pharmaceutical company that experienced softness in its diabetes business in the United States. The company’s US patent for Lantus, its primary insulin drug, expired in 2015, and competition from less expensive biosimilars weighted on Sano-fi’s share price. At the same time, Sanofi’s vaccines business and the specialty care areas its acquired in the purchase of Genzyme did well during the quarter.



From First Eagle Global Value Fund third-quarter 2016 commentary.



Check out First Eagle Investment latest stock trades

Top Ranked Articles about Sanofi SA

New Sanofi insulin savings program aims to lower out-of-pocket costs for people living with diabetes
FDA approves Toujeo® Max SoloStar®
Consolidated Research: 2018 Summary Expectations for Anheuser-Busch InBev SA/NV, Sanofi, Sogou Inc. Sponsored ADR, Unilever, Janus Capital Group, and Kosmos Energy — Fundamental Analysis, Key Performance Indications
Sanofi’s Recent R&D Business Decisions and Developments A quick overview of Sanofi's Business Decisions and Developments aimed to strengthen their portfolio and ensure long term growth and viability.
If you have been following Sanofi it is not a secret that the performance of its stock has much to be desired. Over the last five years, the S&P 500 index has gained nearly 80% in value while Sanofi has fallen approximately 20%. However, Sanofi has made three significant business decisions recently that I believe are worth a closer look and could be a sign of things to change in the future. Read more...
Sanofi and Regeneron announce plans to make Praluent® more accessible and affordable for patients with the greatest health risk and unmet need
Praluent® (alirocumab) Injection significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate
5 Best-Performing Spin-Offs of 2017 Spin-offs tend to have a stellar rate of return, according to research
Spin-offs tend to have a stellar rate of return, according to research. Read more...
Where Are Biotech Industry Vets Taking a Seat at the Table Right Now? Look at Where Deutsche Bank’s Shawn Cross, Pfizer’s Dr. Raymond Urbanski, Chase Pharmaceutical’s Dr. Kathleen Clarence-Smith, and Barker Davis Founder Geoffrey Davis are making their bets
Within the last 12 months we have seen some of the largest biopharma buyouts in history. Last year, Gilead Sciences Inc. (NASDAQ:GILD) acquired Kite Pharma Inc. (NASDAQ:KITE) in a deal that was valued at nearly $12 billion! This year we’ve already begun to see the trend continue after Bioverativ Inc. (NASDAQ:BIVV) was acquired by French biotech company, Sanofi SA ADR (NYSE:SNY) in an $11.6 billion deal. Furthermore, announcements that Celgene Corp. (NASDAQ:CELG) would acquire Juno Therapeutics Inc. (NASDAQ:JUNO) and AbbVie, Inc. (NYSE:ABBV) could seek deals to build onto or complement its early-stage Alzheimer's disease pipeline have kept the fire piping hot for biotech buyouts. With this in mind, there’s no doubt that the future could hold even larger deals in the biopharma space considering immense advancements that this sector is seeing right now. Read more...
Results from Innovative Phase 2 Tuberculosis Vaccine Trial Offer Potential for New BCG Revaccination Strategies, Hope For Subunit Vaccines
Sanofi Delivers 2017 Business EPS in line with Guidance

Ratios

vs
industry
vs
history
PE Ratio 9.72
SNY's PE Ratio is ranked higher than
93% of the 584 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.44 vs. SNY: 9.72 )
Ranked among companies with meaningful PE Ratio only.
SNY' s PE Ratio Range Over the Past 10 Years
Min: 9.52  Med: 16.86 Max: 32.04
Current: 9.72
9.52
32.04
Forward PE Ratio 11.95
SNY's Forward PE Ratio is ranked higher than
84% of the 111 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.00 vs. SNY: 11.95 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 21.66
SNY's PE Ratio without NRI is ranked higher than
61% of the 583 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.44 vs. SNY: 21.66 )
Ranked among companies with meaningful PE Ratio without NRI only.
SNY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.75  Med: 19.7 Max: 32.04
Current: 21.66
9.75
32.04
PB Ratio 1.42
SNY's PB Ratio is ranked higher than
80% of the 843 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.96 vs. SNY: 1.42 )
Ranked among companies with meaningful PB Ratio only.
SNY' s PB Ratio Range Over the Past 10 Years
Min: 1.16  Med: 1.58 Max: 2.33
Current: 1.42
1.16
2.33
PS Ratio 2.27
SNY's PS Ratio is ranked higher than
59% of the 784 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.25 vs. SNY: 2.27 )
Ranked among companies with meaningful PS Ratio only.
SNY' s PS Ratio Range Over the Past 10 Years
Min: 1.76  Med: 2.6 Max: 4.12
Current: 2.27
1.76
4.12
Price-to-Free-Cash-Flow 15.11
SNY's Price-to-Free-Cash-Flow is ranked higher than
73% of the 216 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.03 vs. SNY: 15.11 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
SNY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.49  Med: 14.78 Max: 21.14
Current: 15.11
7.49
21.14
Price-to-Operating-Cash-Flow 11.09
SNY's Price-to-Operating-Cash-Flow is ranked higher than
75% of the 289 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.21 vs. SNY: 11.09 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
SNY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.08  Med: 10.45 Max: 17.15
Current: 11.09
6.08
17.15
EV-to-EBIT 15.32
SNY's EV-to-EBIT is ranked higher than
65% of the 599 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.78 vs. SNY: 15.32 )
Ranked among companies with meaningful EV-to-EBIT only.
SNY' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.1  Med: 16.3 Max: 24.6
Current: 15.32
9.1
24.6
EV-to-EBITDA 9.25
SNY's EV-to-EBITDA is ranked higher than
80% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.59 vs. SNY: 9.25 )
Ranked among companies with meaningful EV-to-EBITDA only.
SNY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.1  Med: 9.15 Max: 14.8
Current: 9.25
5.1
14.8
EV-to-Revenue 2.39
SNY's EV-to-Revenue is ranked higher than
61% of the 810 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. SNY: 2.39 )
Ranked among companies with meaningful EV-to-Revenue only.
SNY' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.9  Med: 2.8 Max: 4.4
Current: 2.39
1.9
4.4
Shiller PE Ratio 15.53
SNY's Shiller PE Ratio is ranked higher than
86% of the 230 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.11 vs. SNY: 15.53 )
Ranked among companies with meaningful Shiller PE Ratio only.
SNY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.64  Med: 19.87 Max: 27.21
Current: 15.53
14.64
27.21
Current Ratio 1.70
SNY's Current Ratio is ranked lower than
67% of the 772 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.56 vs. SNY: 1.70 )
Ranked among companies with meaningful Current Ratio only.
SNY' s Current Ratio Range Over the Past 10 Years
Min: 0.79  Med: 1.65 Max: 2.71
Current: 1.7
0.79
2.71
Quick Ratio 1.26
SNY's Quick Ratio is ranked lower than
67% of the 772 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.02 vs. SNY: 1.26 )
Ranked among companies with meaningful Quick Ratio only.
SNY' s Quick Ratio Range Over the Past 10 Years
Min: 0.59  Med: 1.26 Max: 2.41
Current: 1.26
0.59
2.41
Days Inventory 313.33
SNY's Days Inventory is ranked lower than
93% of the 765 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 116.78 vs. SNY: 313.33 )
Ranked among companies with meaningful Days Inventory only.
SNY' s Days Inventory Range Over the Past 10 Years
Min: 182.05  Med: 209.93 Max: 313.33
Current: 313.33
182.05
313.33
Days Sales Outstanding 72.75
SNY's Days Sales Outstanding is ranked higher than
51% of the 699 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.10 vs. SNY: 72.75 )
Ranked among companies with meaningful Days Sales Outstanding only.
SNY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 67.17  Med: 76.54 Max: 83.73
Current: 72.75
67.17
83.73
Days Payable 145.64
SNY's Days Payable is ranked higher than
82% of the 640 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.92 vs. SNY: 145.64 )
Ranked among companies with meaningful Days Payable only.
SNY' s Days Payable Range Over the Past 10 Years
Min: 104.92  Med: 125.26 Max: 146.55
Current: 145.64
104.92
146.55

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 4.11
SNY's Dividend Yield % is ranked higher than
91% of the 725 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.53 vs. SNY: 4.11 )
Ranked among companies with meaningful Dividend Yield % only.
SNY' s Dividend Yield % Range Over the Past 10 Years
Min: 2.66  Med: 3.84 Max: 5.24
Current: 4.11
2.66
5.24
Dividend Payout Ratio 0.98
SNY's Dividend Payout Ratio is ranked lower than
89% of the 455 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.31 vs. SNY: 0.98 )
Ranked among companies with meaningful Dividend Payout Ratio only.
SNY' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.55  Med: 0.78 Max: 1
Current: 0.98
0.55
1
3-Year Dividend Growth Rate 1.90
SNY's 3-Year Dividend Growth Rate is ranked lower than
63% of the 310 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.30 vs. SNY: 1.90 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
SNY' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -15.6  Med: 7.15 Max: 37.9
Current: 1.9
-15.6
37.9
Forward Dividend Yield % 4.11
SNY's Forward Dividend Yield % is ranked higher than
91% of the 698 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. SNY: 4.11 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 4.57
SNY's 5-Year Yield-on-Cost % is ranked higher than
85% of the 889 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.94 vs. SNY: 4.57 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
SNY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.95  Med: 4.26 Max: 5.81
Current: 4.57
2.95
5.81
3-Year Average Share Buyback Ratio 1.80
SNY's 3-Year Average Share Buyback Ratio is ranked higher than
96% of the 540 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.80 vs. SNY: 1.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SNY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -24.5  Med: 0.2 Max: 2.2
Current: 1.8
-24.5
2.2

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 17.08
SNY's Price-to-Tangible-Book is ranked lower than
91% of the 774 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.80 vs. SNY: 17.08 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SNY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 7.22  Med: 15.27 Max: 41.94
Current: 17.08
7.22
41.94
Price-to-Intrinsic-Value-Projected-FCF 0.79
SNY's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
89% of the 312 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.58 vs. SNY: 0.79 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
SNY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.58  Med: 0.93 Max: 1.45
Current: 0.79
0.58
1.45
Price-to-Median-PS-Value 0.87
SNY's Price-to-Median-PS-Value is ranked higher than
67% of the 692 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.08 vs. SNY: 0.87 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SNY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.71  Med: 1.18 Max: 3.64
Current: 0.87
0.71
3.64
Price-to-Graham-Number 4.05
SNY's Price-to-Graham-Number is ranked lower than
80% of the 425 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.08 vs. SNY: 4.05 )
Ranked among companies with meaningful Price-to-Graham-Number only.
SNY' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.92  Med: 4.28 Max: 6.54
Current: 4.05
1.92
6.54
Earnings Yield (Greenblatt) % 6.52
SNY's Earnings Yield (Greenblatt) % is ranked higher than
77% of the 888 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.96 vs. SNY: 6.52 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SNY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4.1  Med: 6.1 Max: 11
Current: 6.52
4.1
11
Forward Rate of Return (Yacktman) % 4.12
SNY's Forward Rate of Return (Yacktman) % is ranked lower than
59% of the 414 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.53 vs. SNY: 4.12 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
SNY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 0.6  Med: 8.7 Max: 24.8
Current: 4.12
0.6
24.8

More Statistics

Revenue (TTM) (Mil) $41,778.09
EPS (TTM) $ 3.78
Beta0.85
Volatility18.24%
52-Week Range $38.14 - 50.65
Shares Outstanding (Mil)2,496.41 (ADR)

Analyst Estimate

Dec18 Dec19
Revenue (Mil $) 46,537 48,867
EBIT (Mil $) 10,932 13,848
EBITDA (Mil $) 14,728 18,183
EPS ($) 3.52 4.18
EPS without NRI ($) 3.52 4.18
EPS Growth Rate
(Future 3Y To 5Y Estimate)
1.95%
Dividends per Share ($) 1.92 2.13

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}